Compare ORIS & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORIS | INDP |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.0M |
| IPO Year | 2024 | N/A |
| Metric | ORIS | INDP |
|---|---|---|
| Price | $1.52 | $2.95 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 180.5K | ★ 1.7M |
| Earning Date | 04-30-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $12,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $163.69 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.14 | $1.65 |
| 52 Week High | $57.00 | $47.60 |
| Indicator | ORIS | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 96.29 | 61.48 |
| Support Level | $0.06 | $2.19 |
| Resistance Level | $0.11 | $3.15 |
| Average True Range (ATR) | 0.05 | 0.28 |
| MACD | 0.13 | 0.10 |
| Stochastic Oscillator | 85.91 | 83.77 |
Oriental Rise Holdings Ltd is an integrated supplier of tea products in China. It is principally engaged in the business of planting, cultivating, processing, and selling processed tea. The company currently produces and sells three categories of products: roughly processed white tea, roughly processed black tea, and refined tea. The company's business operations are vertically integrated, covering cultivation, processing of tea leaves, and the sale of tea products to tea business operators and end-user retail customers. Geographically, the company generates all of its revenue from its business in the People's Republic of China (the PRC).
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.